Surgeon Faces Misconduct Allegations

The scientist who implanted artificial windpipes into several patients is being accused of conducting the procedures without proper ethical review.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, IJNMIS01The surgeon who claimed to develop functional artificial trachea using plastic fibers and stem cells is being hit with fresh allegations of misconduct, and the patients who received the transplants are not faring well. Thoracic surgeon Paolo Macchiarini of Sweden’s Karolinska Institute has performed a handful of the procedures, including one on a two-year-old girl who subsequently died last year. According to The New York Times, the Karolinska Institute is launching an independent investigation of Macchiarini based on specific complaints filed by doctors who had been involved in the care and treatment of three patients who received the experimental treatment, which is administered under compassionate use rules as it is not approved by federal regulators. “Since the accusations against Dr. Macchiarini are serious and detailed, I considered that they should be thoroughly investigated,” Anders Hamsten, vice chancellor of the institute, told the Times.

The complaints against Macchiarini, which were sent to the Karolinska Institute earlier this year, allege that the surgeon failed to obtain appropriate ethical approvals before operating on the three patients, and that he misled medical journals in which he published accounts of the procedures.

In 2012, Macchiarini was arrested and charged with fraud and attempted extortion in his native Italy, triggering retractions of some of his published work.

The latest allegations hold that the surgeon failed to obtain consent forms from the three patients he treated in Sweden before operating on them. The complainants also claim that Macchiarini knowingly misled journal editors by not reporting serious problems with one of the patients—who later died—before publication of the paper detailing the procedure.

The Times contacted Macchiarini, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies